DEV Community: Modern Industry Insights

Beyond Digitisation: Evaluating Electronic Records and Signatures in Pharma Software

Modern Industry Insights — Thu, 12 Nov 2026 05:23:38 +0000

Moving pharmaceutical documentation from paper to electronic systems can improve accessibility and workflow management. However, digital records introduce important questions about identity, traceability, security and long-term availability.

For teams developing, configuring or implementing software in regulated pharmaceutical environments, 21 CFR Part 11 is an important regulation to understand.

It covers electronic records and electronic signatures within its scope.

Here are some practical questions to consider when evaluating a system:

Can the system generate accurate and complete copies of electronic records?

Are electronic signatures uniquely associated with individuals?

Are signatures permanently linked to their corresponding records?

Does the system maintain secure, time-stamped audit trails?

Can access be restricted according to user authorisation?

Can records be retrieved throughout their applicable retention periods?

Is there documented evidence that the system performs as intended?

These questions connect software functionality with regulatory and operational expectations.

Implementation teams should also consider configuration management, validation, testing, supplier documentation, change control and user training.

A common misconception is that selecting a product labelled Part 11 compliant is enough. In practice, compliance depends on the system's intended use, configuration, validation and the organisation's procedures.

This https://incepbio.com/blog/21-cfr-part-11-compliance-software/ explains the seven key areas and their associated regulatory provisions.

Testing LIMS Software for Pharmaceutical Compliance: A Practical Guide

Modern Industry Insights — Thu, 05 Nov 2026 07:06:54 +0000

Software testing becomes more critical when an application supports activities in a regulated industry. In pharmaceutical laboratories, software is used to manage sample information, laboratory results, calculations, approvals, and quality records.

A Laboratory Information Management System (LIMS) brings many of these activities together. However, how can a pharmaceutical company confirm that the system is actually working as expected?

A successful installation or a basic functional test is not enough. The system must be evaluated against its intended use, and there must be documented evidence that its important functions operate reliably.

This is where LIMS software validation comes into the picture.

Let's look at the key areas that development, testing, IT, and validation teams should consider when working with LIMS in a pharmaceutical environment.

Start With Requirements Before Writing Test Cases

One common mistake in software projects is starting testing before understanding what the application is expected to do.

The same applies to LIMS validation.

Before preparing test cases, teams should understand the laboratory's actual requirements. These may include:

Sample registration and tracking.

Test method assignment.

Result entry and calculations.

Specification limit checks.

Review and approval workflows.

Report generation.

Instrument and application interfaces.

User access and audit trail controls.

These requirements are generally documented in a User Requirements Specification (URS).

Each important requirement should be traceable to the relevant configuration, test case, and test result. This helps demonstrate that the system has been tested against its intended purpose.

Test the Critical Functions of the LIMS

A LIMS may contain several modules, but not every function carries the same level of risk.

Testing should focus on functions that could affect laboratory data, product quality, or GMP activities.

Here are some practical examples.

Sample Registration

Check whether the system creates unique sample identifiers and records the correct sample information.

Test scenarios may include duplicate sample IDs, missing mandatory fields, incorrect batch details, and invalid entries.

Result Calculations

If the LIMS performs calculations, verify the formulas using independently checked values.

Test normal values, boundary conditions, and unexpected inputs to confirm that the system produces the expected output.

Specification Checks

Check whether the system correctly identifies results that fall below, within, or above approved specification limits.

This is particularly important because incorrect specification settings may affect laboratory decisions.

Review and Approval

Verify that the approval workflow follows the laboratory's defined responsibilities.

For example, an analyst should not automatically receive the same approval permissions as an authorised reviewer if the procedure requires separate responsibilities.

Verify Data Integrity and Audit Trails

A LIMS manages electronic laboratory records, so data integrity should be part of the testing strategy.

Testing should establish whether the system maintains appropriate controls over record creation, modification, review, and retention.

Consider this scenario:

An analyst enters a laboratory result but later identifies an error. The result needs correction.

The system should maintain an appropriate record of the original entry and the subsequent change. The audit trail should provide relevant information about who made the change, when it happened, and what was modified.

Other important checks include:

Whether unauthorised users can modify records.

Whether relevant changes are captured in audit trails.

Whether original records remain available.

Whether timestamps and user identities are recorded appropriately.

Whether electronic records can be retrieved when required.

These checks help establish confidence in the reliability and traceability of laboratory information.

Perform Integration Testing Between LIMS and Other Systems

Modern laboratory environments often contain multiple connected applications.

A LIMS may exchange information with:

Laboratory analytical instruments.

Chromatography Data Systems (CDS).

Enterprise Resource Planning (ERP) systems.

Manufacturing Execution Systems (MES).

Electronic Quality Management Systems (eQMS).

A working connection does not necessarily mean that the integration is functioning correctly.

For example, when an analytical instrument transfers a result to the LIMS, teams should verify that the result is associated with the correct sample and that relevant values, units, and metadata remain accurate.

Useful integration test scenarios include:

Successful data transfer.

Incorrect or missing sample identification.

Incomplete data transmission.

Duplicate records.

Interrupted connections.

Rejected or failed transfers.

Verification of data mapping between systems.

Testing these scenarios can help identify problems that may not appear during normal operation.

Check User Permissions and Security Controls

A pharmaceutical LIMS should provide controlled access based on individual responsibilities.

Testing teams should verify whether different user roles have the correct permissions.

For example:

User role

Example responsibility

Laboratory analyst

Laboratory reviewer

Review laboratory records

QA reviewer

Perform assigned quality reviews

System administrator

Manage approved system configurations and user accounts

These are illustrative roles; actual permissions should follow the organisation's approved procedures.

Testing should also verify account management, administrator access, password controls, and relevant electronic signature functions.

Understand the Regulatory Context

LIMS validation is not just another software quality assurance activity. Pharmaceutical organisations must consider the regulatory requirements applicable to their systems.

Some important references include:

EU GMP Annex 11: Expectations for computerised systems used in GMP-regulated activities.

21 CFR Part 11: Requirements for electronic records and electronic signatures within its scope.

21 CFR 211.68: Controls for automatic, mechanical, and electronic equipment.

21 CFR 211.194: Requirements relating to laboratory records.

The validation strategy should reflect the system's intended use, GMP impact, and applicable regulatory framework.

Maintain Testing Evidence and Traceability

In a regulated environment, performing a test is only part of the work. Teams must also document what was tested and what happened.

Typical validation evidence may include:

Approved validation plan.

User Requirements Specification.

Risk assessment.

Functional and configuration specifications.

Test protocols and executed results.

Requirements Traceability Matrix.

Deviation records.

Validation summary report.

The Requirements Traceability Matrix is particularly useful because it connects requirements with their corresponding test cases and results.

It helps teams identify requirements that have not been tested or where testing evidence is incomplete.

Don't Stop Testing After Go-Live

A common misconception is that software validation is complete once the system passes its initial testing and goes live.

In practice, LIMS software may undergo regular updates, configuration changes, interface modifications, and workflow improvements.

These changes can affect previously tested functions.

A change control process should assess the impact of each proposed modification and determine whether additional testing is required.

Periodic reviews should also consider system access, audit trails, incidents, software updates, and the continued suitability of the application.

Final Thoughts

Testing LIMS software in a pharmaceutical environment requires more than checking whether individual features work. Teams must understand the laboratory workflow, identify critical functions, verify data integrity, test system interfaces, and maintain documented evidence.

A risk-based approach helps focus testing on the functions that matter most while maintaining appropriate control over the system lifecycle.

For a deeper explanation of the requirements involved, see this guide: LIMS Validation in Pharma: 7 Key Requirements for GMP Compliance.

A Practical Approach to Evaluating Airflow Visualisation in GMP Cleanrooms

Modern Industry Insights — Mon, 02 Nov 2026 05:38:13 +0000

Pharmaceutical cleanrooms depend on controlled airflow to protect exposed products, components and critical surfaces. In aseptic manufacturing, smoke studies help teams visualise airflow behaviour under defined operating conditions.

However, capturing a video of smoke movement is not enough. The observations must be assessed against predefined acceptance criteria to determine whether the airflow pattern provides the intended protection.

This article outlines a practical approach to reviewing airflow visualisation results in GMP cleanrooms.

Define the Expected Airflow Behaviour

Before conducting a smoke study, identify what the test is intended to demonstrate.

The protocol should consider:

Cleanroom layout and equipment configuration

Critical process locations and exposed products

Intended airflow direction

Relevant operating conditions

Routine interventions and operator movements

Potential contamination pathways

The expected airflow behaviour should be clear enough for reviewers to compare actual observations with the predefined criteria.

Capture Representative Operating Conditions

Airflow can change when operators interact with equipment or move materials through a critical area.

A study should therefore consider relevant operating conditions, rather than relying only on observations made in an unoccupied room.

Depending on the process, the protocol may include material transfer, equipment handling, component replacement and other representative interventions.

Video recordings should clearly show the test location, the activity being performed and the resulting smoke movement.

Evaluate Airflow Observations Systematically

A structured review helps teams avoid relying on subjective impressions of whether airflow looks acceptable.

The following table summarises useful observation points.

Observation

What to assess

Airflow direction

Whether air moves in the intended direction

Product protection

Whether exposed products and critical surfaces receive appropriate protection

Turbulence and eddies

Whether local disturbances affect critical locations

Operator interventions

Whether activities disrupt the intended airflow pattern

Reversal or ingress

Whether air moves from less clean areas towards higher-grade areas

Smoke clearance

Whether slow-moving or stagnant patterns require further assessment

Not every visible disturbance represents a failure. Its significance depends on its location, duration, operating conditions and potential effect on product protection.

Review Interventions and Local Disturbances

Operator movements and equipment arrangements can create local airflow disturbances.

For example, an intervention near an exposed product may influence the airflow pattern around that location. Reviewers should examine the video to understand whether the disturbance affects the intended protective airflow.

The assessment should record the observation, its location and the conditions under which it occurred. Where a potential contamination risk is identified, it should be evaluated and documented through the site's quality system.

Establish Acceptance Criteria Before Execution

Acceptance criteria should be defined before the study begins. They should reflect the facility design, process requirements and contamination risks.

EU GMP Annex 1 addresses airflow visualisation and the need to demonstrate appropriate airflow protection in cleanrooms and critical areas. It does not establish one universal numerical pass/fail limit for every visible smoke pattern.

Manufacturers should therefore define and justify study-specific criteria through documented risk assessment and approved procedures.

Maintain Traceable Study Records

A review is only useful when its conclusions can be traced back to the evidence.

Depending on the approved protocol, the study record may include:

Approved protocol and acceptance criteria

Test locations and operating conditions

Equipment configuration and relevant interventions

Smoke-generation details

Original video recordings

Annotated footage and observation logs

Assessment of observations against criteria

Deviations and investigations, where applicable

Review and approval records

Timestamps and location references can make it easier to connect a finding in the report with the corresponding video evidence.

Distinguish Smoke Visualisation from Recovery Testing

Smoke visualisation and cleanroom recovery testing provide different types of evidence.

Smoke studies demonstrate visible airflow behaviour. They help teams understand airflow direction, local disturbances and the influence of interventions.

Recovery testing evaluates how quickly a cleanroom returns to a specified particle-cleanliness condition after a defined challenge.

Visible smoke clearance should not be treated as proof of particle recovery or restoration of the qualified cleanroom state.

Conclusion

A structured smoke study review connects airflow observations with predefined acceptance criteria and the protection required by the process.

By evaluating airflow direction, product protection, turbulence, interventions, potential ingress and supporting documentation, pharmaceutical teams can make more consistent assessments of cleanroom airflow behaviour.

The conclusions should always be based on the approved protocol, facility design and contamination-control requirements.

For a more detailed discussion of smoke study acceptance criteria and airflow risk assessment, see IncepBio's guide to smoke study acceptance criteria.

Brownfield CQV: What Software and Automation Changes Mean for GMP Compliance

Modern Industry Insights — Thu, 29 Oct 2026 05:23:32 +0000

In a pharmaceutical facility, a seemingly small automation change can affect a larger qualified system.

A revised PLC sequence, new SCADA interface, changed alarm limit, or additional EMS sensor may influence functions that have already been tested and approved. The challenge is not simply to confirm that the new function works. It is to determine whether related functions and GMP records remain reliable.

Identify the Change Boundary

Document the modified component and its connections to existing systems. Consider control logic, alarms, interlocks, user access, data transfers, and affected equipment.

Assess the GMP Impact

Determine which functions could affect product quality, process control, environmental conditions, or GMP records. Use the documented risk assessment to define the testing scope.

Test Changed and Related Functions

Testing may include:

Functional testing of modified logic

Alarm and interlock challenges

Regression testing of related functions

Verification of data transfers where relevant

Review of configuration backups and access controls where applicable

The exact tests should follow the change assessment and approved site procedures.

Maintain Controlled Records

Retain the approved change record, configuration documentation, test evidence, deviations, and final reports. Update relevant specifications and procedures before the modified system is released for GMP use.

EU GMP Annex 11 addresses computerised systems, while Annex 15 provides relevant expectations for qualification, validation, and change control. GAMP 5 supports a risk-based approach but does not replace applicable regulations.

The key lesson: test the impact of the change, not only the component that changed.

pharma #automation #GMP #validation #CQV

What Software Teams Should Understand About CSV in Pharma

Modern Industry Insights — Tue, 27 Oct 2026 05:33:15 +0000

What Software Teams Should Understand About CSV in Pharma

Software used in pharmaceutical GxP processes has a different context from an ordinary business application. Its intended use, potential impact and applicable requirements influence the validation evidence and controls that an organisation needs.

For developers, QA engineers and implementation teams, several principles are worth understanding.

Requirements Must Be Traceable

Requirements should connect to risk assessments, test cases, test results and deviations. This relationship helps reviewers understand whether the intended functions were assessed and how exceptions were resolved.

Testing Should Reflect Risk

The depth of testing should be justified by intended use and risk. Teams should document why particular functions require specific testing and retain evidence supporting their decisions.

Auditability Is Part of the Design

Access controls, audit trails, approval records and electronic signatures need to be evaluated in the context of the applicable requirements. Simply adding an audit-log feature does not prove that the complete system is suitable for regulated use.

Changes Need an Assessment Process

New releases, configuration changes and updates can affect system behaviour. Teams should establish a process for assessing impact, deciding on testing and retaining the resulting evidence.

Tools Do Not Replace Accountability

A CSV platform may organise requirements, testing, documentation and approvals. However, the regulated organisation remains responsible for ensuring the system is suitable for its intended use and operated under appropriate controls.

If you work on software implementation or quality engineering in pharma, this broader guide to https://incepbio.com/blog/computer-system-validation-software/ covers selection criteria, traceability and supplier evaluation.

The most useful validation workflow is one that connects technical evidence to clear requirements, risk decisions and accountable review.

Computer System Validation in Pharma: A Practical Guide to Risk-Based Testing

Modern Industry Insights — Sat, 24 Oct 2026 06:26:26 +0000

Software used in pharmaceutical operations does more than automate workflows. It may manage laboratory results, manufacturing records, quality processes, and other data that support regulated activities.

When software affects product quality, patient safety, or data integrity, teams need documented evidence that it performs as intended. This is where Computer System Validation (CSV) becomes important.

For developers, QA engineers, business analysts, and validation professionals, understanding CSV helps connect software development and testing practices with pharmaceutical compliance requirements.

What Does Computer System Validation Mean?

Computer System Validation is a documented process for demonstrating that a computerized system is suitable for its intended use.

Unlike testing focused only on whether a feature works, CSV considers whether the system meets defined requirements and whether the evidence is sufficient for its regulated purpose.

Examples of computerized systems in pharmaceutical environments include:

Laboratory Information Management Systems (LIMS)

Manufacturing Execution Systems (MES)

Electronic Quality Management Systems (eQMS)

Laboratory data management applications

Systems that maintain regulated electronic records

The validation scope depends on the system's intended use, complexity, risks, and applicable regulations.

Step 1: Define Clear Requirements

Testing becomes difficult when requirements are incomplete or ambiguous.

Before implementation or validation, document what the system must do. Requirements may cover business functions, user permissions, data handling, interfaces, reporting, and relevant audit trail controls.

Each requirement should be clear enough to support verification.

For example, instead of stating that a system must provide secure access, define the expected access-control behaviour and how it will be verified.

Step 2: Use Risk Assessment to Guide Testing

Not every software function has the same impact.

A failure affecting critical manufacturing data may have more serious consequences than a failure in a non-critical display feature.

A risk assessment helps teams identify important functions and determine appropriate testing activities.

Consider:

What could go wrong?

Which process or data could be affected?

Could the failure affect product quality, patient safety, or data integrity?

What controls are needed to reduce the risk?

What evidence is required to demonstrate that those controls work?

Document the rationale behind testing decisions instead of relying on assumptions.

Step 3: Build Traceability Between Requirements and Tests

Traceability helps demonstrate that requirements have been addressed through appropriate verification.

A requirements traceability matrix can connect each requirement to its corresponding test cases and results.

For example:

Requirement

Test approach

Expected evidence

Only authorized users can access restricted functions

Verify access permissions for relevant user roles

Recorded test results

Critical data changes are traceable

Verify applicable audit trail functionality

Test evidence and review records

Data transfers correctly between systems

Test relevant interface scenarios

Input-output comparison and recorded results

The actual requirements and tests should reflect the system's intended use and applicable controls.

Step 4: Document Test Results and Investigate Failures

A test passing in a development environment does not automatically demonstrate that the implemented system is suitable for regulated use.

Validation evidence should identify the test performed, expected result, actual result, and any relevant deviations.

When a test fails, investigate the cause and document the resolution. Determine whether the failure affects other requirements or previously completed tests.

Good documentation makes testing decisions easier to review and supports future troubleshooting.

Step 5: Assess Supplier Evidence and Dependencies

Modern applications often rely on vendor software, third-party libraries, external services, and system interfaces.

Supplier documentation and existing test evidence can support validation when their suitability has been assessed.

However, teams should not assume that supplier testing automatically covers every configuration or intended use within their own environment.

Identify the boundaries of supplier evidence, document relevant gaps, and perform additional verification where necessary.

Step 6: Manage Changes After Release

Software changes can affect previously tested functionality.

Updates, configuration changes, new integrations, and permission changes should be assessed through an appropriate change-control process.

A useful change assessment considers:

Which requirements and functions are affected?

What new risks could the change introduce?

Which existing tests remain relevant?

Is additional testing necessary?

What documentation and approvals are required?

This approach helps teams maintain confidence in the system throughout its operational lifecycle.

Common CSV Challenges for Software Teams

Several challenges can make validation harder:

Unclear requirements: Teams cannot reliably verify behaviour that has not been defined.

Insufficient test coverage: Important functions or interfaces may remain untested.

Weak traceability: Reviewers may struggle to connect requirements with test evidence.

Incomplete deviation records: Failures may be resolved without sufficient documented justification.

Poor change management: Updates may affect validated functions without adequate impact assessment.

Addressing these issues during planning and development can reduce avoidable rework.

Bringing Software Engineering and Compliance Together

Computer system validation works best when requirements, risk assessment, testing, documentation, and change management are considered throughout the software lifecycle.

Developers and QA teams can contribute by writing testable requirements, maintaining traceability, producing clear test evidence, and documenting changes. Validation and quality teams can then assess whether the overall evidence supports the system's intended use.

For a broader explanation of validation stages and documentation, see IncepBio's guide to the https://incepbio.com/blog/computer-system-validation-process/.

Conclusion

Computer System Validation connects software quality practices with the evidence needed in regulated pharmaceutical environments.

Clear requirements, risk-based testing, traceability, documented results, and controlled changes help demonstrate that computerized systems are suitable for their intended use. The precise approach should always reflect the system's risks and applicable regulatory requirements.

From Equipment Requirements to Testing: A Practical Guide to IQ, OQ and PQ

Modern Industry Insights — Wed, 21 Oct 2026 09:59:53 +0000

Pharmaceutical manufacturing equipment is often connected to sensors, control systems, alarms, interlocks, and electronic records. Verifying that a machine starts correctly is only the beginning. Teams also need evidence that its relevant functions meet defined requirements and support its intended GMP use.

A useful way to approach this is to connect requirements, risk assessment, testing, and documentation from the start.

Define Requirements Before Testing

Begin with a User Requirements Specification (URS). It should describe what the equipment must do, including relevant process needs, operating ranges, utilities, cleaning requirements, and data requirements.

Requirements should be specific enough to support meaningful verification. If a requirement cannot be linked to a test or other documented verification activity, the team should review whether the requirement or its verification approach needs clarification.

Use Risk to Set the Scope

Not every function has the same impact on product quality or patient safety. A risk assessment helps identify critical functions and parameters, then justifies the scope and depth of qualification.

This avoids two common problems: unnecessary testing of low-risk functions and insufficient testing of critical ones.

Organise DQ, IQ, OQ and PQ

DQ: Review the proposed design against user requirements.

IQ: Verify installation, components, utility connections, documentation, and calibration status as applicable.

OQ: Challenge operating functions, alarms, interlocks, and defined parameter ranges.

PQ: Demonstrate consistent performance under representative routine conditions.

Acceptance criteria should be approved before execution. Results must be recorded, and failures or unexpected outcomes should be handled through approved deviation procedures.

Make Traceability Part of the Workflow

A traceability matrix can link each requirement to its verification activity, result, and associated deviation. The final report should summarise the evidence and state the conclusion on suitability for intended use.

For automated equipment, teams should also assess whether software functions, electronic records, alarms, and access controls fall within the scope of computerised system validation.

Plan for Changes

Equipment qualification does not replace maintenance, calibration, or change control. Modifications, software updates, and major repairs should be assessed for their potential impact on the qualified state.

For a broader explanation of the stages and GMP documentation involved, see this https://incepbio.com/blog/pharmaceutical-equipment-qualification/ guide.

The strongest workflow is one in which requirements, risks, tests, and conclusions remain connected throughout the equipment lifecycle.

Plan for Changes

For a broader explanation of the stages and GMP documentation involved, see this pharmaceutical equipment qualification guide.

The strongest workflow is one in which requirements, risks, tests, and conclusions remain connected throughout the equipment lifecycle.

System Integration in Pharma: Connecting PLC, SCADA, MES and Enterprise Applications

Modern Industry Insights — Thu, 15 Oct 2026 07:36:36 +0000

Connecting industrial systems is not simply a matter of making two applications communicate. In pharmaceutical manufacturing, interfaces must transfer the correct information reliably, preserve its context, and support controlled operations.

Start With the Data Flow

Before implementation, map the systems and the information each one owns.

For example:

PLCs generate equipment states, process values, and interlock signals.

SCADA systems collect operational data, alarms, and trends.

MES coordinates production execution and batch records.

ERP manages production orders and material information.

QMS and LIMS support quality events and laboratory results.

Not every system needs a direct connection to every other system. A clear interface architecture helps reduce unnecessary dependencies.

Common Integration Challenges

Legacy equipment may use communication protocols that differ from modern platforms. Data structures may be inconsistent, and unclear ownership can create confusion when an interface fails.

Useful engineering practices include defining interface specifications, validating data mappings, testing communication failures, documenting alarm handling, and establishing change-control procedures.

In regulated environments, validation activities should be based on intended use and risk. Audit trails, user permissions, data integrity, and system lifecycle responsibilities also require attention.

For an overview of the seven operational benefits and the considerations involved in selecting an integration partner, see Pharma Automation Integration Services.

Smoke Study Video Review: A Practical Checklist for Pharmaceutical QA Teams

Modern Industry Insights — Tue, 13 Oct 2026 06:03:51 +0000

In pharmaceutical cleanrooms, airflow visualization helps teams understand how air moves around exposed products, critical surfaces, equipment, and operators during aseptic operations.

But recording a smoke study is only half the job.

The recorded footage must be reviewed to determine whether it provides sufficient evidence of airflow protection under the conditions defined in the approved protocol. This is where a structured Smoke Study Video Review becomes important.

For Quality Assurance (QA), validation, and engineering teams, the challenge is not simply identifying unusual smoke movement. It is determining what the observation means, whether it meets predefined acceptance criteria, and how the conclusion should be documented.

Here is a practical nine-point checklist for reviewing smoke study footage.

1. Verify the Study Configuration

Before interpreting the airflow, confirm that the video represents the approved study setup.

Check:

Protocol version and study identification.
Room and equipment configuration.
Smoke source and test conditions.
At-rest or in-operation state.
Relevant supporting airflow measurements.

If the recorded setup differs from the approved protocol, document the discrepancy and evaluate its impact before accepting the results.

This prevents reviewers from drawing conclusions from footage that does not represent the intended conditions.

2. Check Whether Critical Areas Are Visible

A video may contain extensive footage but still fail to demonstrate what matters.

Review whether the camera clearly captures the exposed product, critical surfaces, relevant equipment, and operator activities.

For example, if an operator's arm blocks the view of a filling point during an intervention, the reviewer may be unable to determine whether airflow protection was maintained.

Record the timestamp and location of any visibility gap. Then assess whether the available evidence is sufficient or whether supplementary footage or repeat testing is needed.

3. Evaluate First-Air Protection

First air is filtered air that reaches exposed product or critical surfaces before contacting other objects that could compromise its protective function.

During the review, follow the visible airflow path toward the critical zone.

Ask:

Does the airflow reach the exposed product as intended?
Do operator movements interfere with the airflow path?
Does equipment obstruct the intended air movement?
Is there evidence of a potential contamination risk?

EU GMP Annex 1 paragraphs 4.4 and 4.19 address protection of critical zones and first-air protection in relevant contexts.

An observation should be assessed against the approved protocol and supporting evidence rather than classified as a failure based on appearance alone.

4. Review Dynamic Operations and Operator Interventions

Airflow can behave differently when operators perform routine activities.

Examples include material replenishment, equipment adjustments, and interventions near critical processing areas.

Compare the recorded activities with the interventions defined in the approved protocol. Check whether the footage represents the intended operating conditions and whether important activities are missing.

EU GMP Annex 1 paragraph 8.16 addresses authorized lists of inherent and corrective interventions, taking their potential impact on airflow into account.

If a critical intervention was not recorded, document the gap and assess whether the study remains adequate for its intended purpose.

5. Interpret Turbulence and Reversal in Context

Smoke visualization may show eddies, turbulence, temporary reversals, or changes in airflow direction.

These observations are not automatically failures.

Their significance depends on factors such as:

Location of the disturbance.
Duration and frequency.
Proximity to exposed products.
Interaction with operator movements or equipment.
Evidence of maintained or restored protection.

For example, a temporary disturbance away from a critical surface may require a different assessment from airflow that visibly carries contamination from an operator toward an exposed product.

The review should document what was observed, evaluate the potential risk, and compare the evidence with the approved acceptance criteria.

6. Verify Coverage of Critical Locations

A review should confirm that all protocol-defined locations and scenarios are represented in the footage.

Depending on the facility, these may include filling points, exposed product pathways, equipment interfaces, and locations affected by interventions.

For barrier systems, EU GMP Annex 1 paragraph 4.20 addresses airflow pattern studies at relevant open-isolator interfaces and during RABS interventions, including door openings.

A simple location-by-location review can help identify missing evidence before the final report is approved.

7. Compare Findings with Predefined Acceptance Criteria

Once observations have been recorded, compare them with the approved acceptance criteria.

Avoid relying solely on subjective descriptions such as “good airflow” or “acceptable smoke movement.” The reviewer should explain how the evidence supports the conclusion required by the protocol.

Acceptance criteria should be established before reviewing the results. If they are inadequate, the issue should be addressed through the site's quality and change-control procedures rather than by adjusting criteria to fit the observed outcome.

Neither EU GMP Annex 1 nor the FDA's aseptic processing guidance provides a universal set of pass/fail thresholds for every smoke study video review.

8. Document Deviations and Follow-Up Actions

Unexpected airflow patterns, incomplete footage, or differences between the approved and actual setup may require investigation.

A useful review record should identify:

The observation and timestamp.
The affected location and operating activity.
The relevant acceptance criterion.
The potential impact on product protection.
The conclusion and required follow-up.

Where necessary, follow the site's deviation management process and determine whether corrective and preventive actions (CAPA) are appropriate.

If footage contains repeated takes or edited clips, retain the original recordings and document why the additional versions were created.

9. Maintain Video and Report Traceability

The final check is documentation integrity.

Verify that:

Video file identifiers match the report.
Timestamps correspond to the observation log.
Location labels are consistent.
Original recordings are retained alongside edited clips.
Deviations and follow-up actions are traceable.
Final conclusions match the approved protocol and acceptance criteria.

EU GMP Annex 1 paragraph 4.15 addresses the retention of airflow visualization recordings and documentation of outcomes.

Traceability allows another qualified reviewer to understand the evidence and follow the reasoning behind the final decision.

A Practical Example: Reviewing an Airflow Observation

Consider a hypothetical scenario in which smoke near an operator's forearm briefly moves toward an exposed product during a manual intervention.

The reviewer should not immediately classify the study as failed.

Instead, the review should establish:

Observation: Smoke movement toward the critical area.
Context: The intervention being performed and the location involved.
Evidence: The complete video sequence and relevant supporting data.
Assessment: Whether the movement compromises the protection required by the approved protocol.
Outcome: A documented conclusion and any necessary investigation or repeat testing.

This approach separates an observation from the decision made about it.

How EU GMP Annex 1 and FDA Guidance Fit Into the Review

EU GMP Annex 1 (2022), paragraph 4.15, addresses airflow visualization at rest and in operation, with video recordings retained and outcomes documented.

The FDA's guidance on sterile drug products produced by aseptic processing also discusses in situ airflow pattern analysis under dynamic conditions and documentation of conclusions.

These sources provide regulatory context for smoke study evaluation. However, the nine checks in this article are a practical review framework, not a verbatim regulatory checklist.

Facilities should define responsibilities, acceptance criteria, and documentation requirements through their approved protocols and quality systems.

Final Thoughts

A reliable Smoke Study Video Review requires more than watching smoke move through a cleanroom. It requires reviewers to connect the recorded evidence with the study protocol, operational conditions, contamination risks, and documented acceptance criteria.

For QA and validation teams, a structured checklist makes it easier to identify missing evidence, investigate potential concerns, and explain the final decision.

For a more detailed guide, see Smoke Study Video Review: 9 Essential Checks for QA Teams.

You can also explore IncepBio's cleanroom validation services for information about static and dynamic smoke studies in pharmaceutical manufacturing.

This article is intended for educational purposes. Study-specific decisions should follow applicable regulatory requirements, approved protocols, risk assessments, and site procedures.

Managing Pharma Validation Workflows: Planning, Documentation, and Digital Tools

Modern Industry Insights — Mon, 12 Oct 2026 04:57:54 +0000

Pharmaceutical validation involves more than executing tests. Teams must manage requirements, protocols, results, deviations, approvals, and project dependencies while following established quality procedures.

As the number of projects increases, manual tracking can make it harder to understand what is complete, what is delayed, and what needs attention.

Treat the Validation Ca lendar as a Planning Tool

Track upcoming qualification activities, periodic reviews, project milestones, and resource requirements. An integrated schedule helps teams identify conflicts before they affect other activities.

Improve Documentation Visibility

Use consistent templates, controlled document versions, clear ownership, and a tracker for open actions. This makes it easier to follow review progress and identify overdue documentation.

Identify Resource and Skill Gaps

Review the technical skills and instruments required for upcoming projects. Cleanroom testing, thermal mapping, equipment qualification, and computerized system activities may require different expertise.

Use Digital Tools Carefully

Digital validation tools can help organize records and monitor workflow status. However, their suitability depends on intended use, configuration, access controls, data integrity measures, and appropriate validation or assurance activities.

Software does not replace approved procedures or quality oversight.

Review the Need for Additional Support

If recurring workloads exceed internal capacity, teams can assess whether training, project-based specialists, or ongoing engineering support would be appropriate.

This overview explains the five signs a pharmaceutical team may need continuous validation support.

Conclusion

Better validation workflows begin with clear planning, reliable documentation, and visibility into resources. Combining these practices with suitable digital tools and specialist support can help pharmaceutical teams manage complex workloads more effectively.

Digital Validation Software: 7 Manual Validation Challenges in Pharma

Modern Industry Insights — Fri, 09 Oct 2026 05:23:38 +0000

Pharmaceutical validation involves a lot of documentation, reviews, approvals, and record tracking. When these activities are managed through spreadsheets, paper files, and emails, keeping everything organized can become difficult.

This is especially true when multiple projects and teams are working on equipment qualification, cleanroom validation, and other validation activities.

Here are seven common challenges pharmaceutical teams may face when relying heavily on manual processes.

Scattered Documentation

Protocols, reports, test results, and supporting documents may be stored in different folders or email threads. Finding the correct record can take time.

Protocol Version Confusion

When several versions of a protocol exist, team members may struggle to identify the latest approved document. Clear version control helps reduce this risk.

Slow Review and Approval

Paper-based reviews and email follow-ups can delay approvals, particularly when several people need to review the same document.

Limited Project Visibility

Without a clear overview of ongoing activities, it can be difficult to identify overdue tasks, pending reviews, and project delays.

Manual Status Tracking

Updating spreadsheets and repeatedly following up with team members takes time that could be spent on technical validation work.

Difficult Audit Preparation

Finding historical records, approval details, and supporting evidence can become stressful when information is spread across multiple locations.

Data Entry Errors

Repeatedly transferring information from paper records into spreadsheets and reports can introduce transcription errors. Appropriate review procedures and data integrity controls remain essential.

How Can Digital Validation Software Help?

Digital validation software can help pharmaceutical teams organize documentation, manage workflows, track activities, and retrieve records more efficiently.

Depending on the platform, features may include controlled document access, version history, approval workflows, task notifications, and searchable records.

However, software alone does not guarantee GMP compliance. Companies must assess and validate systems for their intended use and maintain appropriate procedures, training, and quality oversight.

Final Thoughts

Moving from manual to digital validation management is not simply about replacing paper with software. It is about making documentation, reviews, and validation activities easier to manage while maintaining control and traceability.

If you're interested in the topic, this article explores the seven challenges in more detail:

https://incepbio.com/blog/digital-validation-software-pharma/

Discussion: Which manual validation challenge creates the most difficulty for your team: document control, approvals, status tracking, or audit preparation?

Smoke Studies & Airflow Visualization in GMP Cleanrooms

Modern Industry Insights — Thu, 01 Oct 2026 05:33:34 +0000

How can you actually see whether airflow is protecting critical zones during cleanroom operations?

Smoke studies (airflow visualization) help identify:

Airflow turbulence and dead zones
Reverse airflow
First-air protection risks
Differences between at-rest and in-operation conditions

Join IncepBio for a FREE LIVE WEBINAR covering practical smoke study approaches, common audit observations, and contamination-control considerations.

📅 9 October 2026 | 10:30 AM–12:00 PM IST
🎙️ Gaurav Dakshini PMP® ATP
💻 Live Online | Free Registration

👉 Register: https://lnkd.in/gmUDxV_K